<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980028</url>
  </required_header>
  <id_info>
    <org_study_id>18 HLGENF 01</org_study_id>
    <nct_id>NCT03980028</nct_id>
  </id_info>
  <brief_title>Role of Surgery in Advanced Ovarian Cancer</brief_title>
  <official_title>Role of Surgery in Advanced Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut Paoli-Calmettes</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Vall d'Hebron</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate that ultra-radical surgery with multiple visceral resections and high tumor
      burden prior to surgery independently reduces the survival of patients with advanced ovarian
      cancer treated with complete cytoreductive surgery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective :

      To demonstrate that ultra-radical surgery with multiple visceral resections and high tumor
      burden prior to surgery independently reduces the survival of patients with advanced ovarian
      cancer treated with complete cytoreductive surgery.

      Secondary objectives:

        1. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated
           by complete cytoreduction surgery, the high tumor load before surgery decreases
           survival. / Evaluate whether there is a sub-group of patients at risk for whom the high
           tumor burden prior to surgery reduces survival.

        2. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated
           by complete cytoreduction surgery, the extension of carcinomatosis to the upper abdomen
           reduces the chances of survival. / Assess whether there is a subgroup of patients at
           risk for whom the extension of carcinomatosis to the upper abdomen reduces survival.

        3. Demonstrate that, in patients with advanced ovarian cancer (FIGO Stage IIIC-IVB) treated
           by complete cytoreduction surgery, invasion of the celiac lymph nodes reduces survival
           rates. / Assess whether there is a subset of patients at risk where the invasion of the
           celiac lymph nodes reduces survival.

        4. Demonstrate that, in patients with advanced ovarian cancer (FIGO stage IIIC-IVB) treated
           with complete cytoreduction surgery, combination with surgical procedures reduces
           survival. / Evaluate whether there is a sub-group of at-risk patients for whom the
           combination of surgical procedures with ultra-radical surgery reduces survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">June 1, 2019</completion_date>
  <primary_completion_date type="Actual">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Patient survival</measure>
    <time_frame>4 years</time_frame>
    <description>patient survival after surgery (patient record)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Evaluation of the tumor burden</measure>
    <time_frame>1 day</time_frame>
    <description>Measurement of tumor size before surgery (patient record)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the extension of carcinomatosis</measure>
    <time_frame>1 day</time_frame>
    <description>Number of tumor nodules before surgery (patient record)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the invasion of celiac lymph nodes</measure>
    <time_frame>1 day</time_frame>
    <description>Number of celiac lymph nodes before surgery (patient record)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combination of surgical procedures</measure>
    <time_frame>1 day</time_frame>
    <description>Number and type of combination of surgical procedures (patient record)</description>
  </secondary_outcome>
  <enrollment type="Actual">550</enrollment>
  <condition>Ovarian Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        patients diagnosed with advanced epithelial ovarian cancer (IIIC-IVB of FIGO 2014) treated
        with cytoreduction surgery between 2008, January and 2015, December
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed histological diagnosis of ovarian epithelial cancer

          -  complete cytoreduction surgery

        Exclusion Criteria:

          -  women under 18 years or presence of residual tumor &gt;2.5mm after surgery or lack of
             data on performed surgical procedures or surgery performed before 2008, January or
             after 2015, Decembrer.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>ovarian cancer</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Claudius Regaud - IUCT-Oncopole</name>
      <address>
        <city>Toulouse</city>
        <state>Occitanie</state>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Bristow RE, Chi DS. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol. 2006 Dec;103(3):1070-6. Epub 2006 Jul 27.</citation>
    <PMID>16875720</PMID>
  </results_reference>
  <results_reference>
    <citation>Vergote I, Tropé CG, Amant F, Kristensen GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ, Panici PB, Kenter GG, Casado A, Mendiola C, Coens C, Verleye L, Stuart GC, Pecorelli S, Reed NS; European Organization for Research and Treatment of Cancer-Gynaecological Cancer Group; NCIC Clinical Trials Group. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53. doi: 10.1056/NEJMoa0908806.</citation>
    <PMID>20818904</PMID>
  </results_reference>
  <results_reference>
    <citation>du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer. 2009 Mar 15;115(6):1234-44. doi: 10.1002/cncr.24149.</citation>
    <PMID>19189349</PMID>
  </results_reference>
  <results_reference>
    <citation>Eisenkop SM, Spirtos NM, Friedman RL, Lin WC, Pisani AL, Perticucci S. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003 Aug;90(2):390-6.</citation>
    <PMID>12893206</PMID>
  </results_reference>
  <results_reference>
    <citation>Chi DS, Franklin CC, Levine DA, Akselrod F, Sabbatini P, Jarnagin WR, DeMatteo R, Poynor EA, Abu-Rustum NR, Barakat RR. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol. 2004 Sep;94(3):650-4.</citation>
    <PMID>15350354</PMID>
  </results_reference>
  <results_reference>
    <citation>Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR. Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol. 2009 Jul;114(1):26-31. doi: 10.1016/j.ygyno.2009.03.018. Epub 2009 Apr 23.</citation>
    <PMID>19395008</PMID>
  </results_reference>
  <results_reference>
    <citation>Chi DS, Zivanovic O, Levinson KL, Kolev V, Huh J, Dottino J, Gardner GJ, Leitao MM Jr, Levine DA, Sonoda Y, Abu-Rustum NR, Brown CL, Barakat RR. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010 Oct;119(1):38-42. doi: 10.1016/j.ygyno.2010.05.031. Epub 2010 Jul 6.</citation>
    <PMID>20609464</PMID>
  </results_reference>
  <results_reference>
    <citation>Schulman-Green D, Ercolano E, Dowd M, Schwartz P, McCorkle R. Quality of life among women after surgery for ovarian cancer. Palliat Support Care. 2008 Sep;6(3):239-47. doi: 10.1017/S1478951508000497.</citation>
    <PMID>18662417</PMID>
  </results_reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 4, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>June 6, 2019</last_update_submitted>
  <last_update_submitted_qc>June 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgery</keyword>
  <keyword>cancer</keyword>
  <keyword>ovarian</keyword>
  <keyword>advanced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <study_docs>
    <study_doc>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.iuct-oncopole.fr/recherches-necessitant-une-reutilisation-de-donnees</doc_url>
      <doc_comment>All the information is provided on this web page in accordance with the RGPD regulations</doc_comment>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

